Anti-PD-1 and Anti-CD27 Antibody Combination for Cancer Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer immunotherapy combinations do not have an acceptable safety profile and high efficacy for enhancing antitumor immune responses compared to monotherapy and other immunotherapy combinations.

Innovation Solution

Administering a combination of an anti-Programmed Death-1 (PD-1) antibody and an anti-CD27 antibody to subjects with cancer, specifically for treating cancers such as colorectal, lung, melanoma, ovarian, and head and neck cancers.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If combination immunotherapy is used to enhance antitumor immune responses, then efficacy is improved, but safety profile deteriorates

Engineering Contradiction:

ImproveefficacyVSAvoidsafety profile

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the parameter of immune checkpoint inhibition by combining anti-PD-1 antibody with anti-CTLA-4 antibody, creating a dual-checkpoint inhibition regimen that modifies the immunotherapeutic approach to achieve both enhanced efficacy and acceptable safety profile

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite immunotherapy regimen by combining two different monoclonal antibodies (anti-PD-1 and anti-CTLA-4) that target different immune checkpoint pathways, thereby achieving synergistic antitumor effects while managing safety concerns

Inventive Principle:

Principle #40Composite materials

2Reliability

If combination immunotherapy is used to enhance antitumor immune responses, then antitumor efficacy is improved, but treatment complexity increases

Engineering Contradiction:

Improveantitumor efficacyVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges two immunotherapeutic agents (anti-PD-1 and anti-CTLA-4 antibodies) into a single combination treatment regimen, consolidating multiple therapeutic mechanisms into one integrated approach that enhances antitumor efficacy while streamlining treatment delivery

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20250154274A1Use of Anti-PD-1 antibody in combination with Anti-CD27 antibody in cancer treatment

Publication Date: 2025.05.15 BRISTOL MYERS SQUIBB CO

AI summary

This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.